Company ProfilePremium

Alembic Pharma

Company Profile Analysis

Tickers: APLLTD.NS, 533573.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Alembic Pharma - Company showcase

Year Founded & Workforce

1907

17,200 Employees

Alembic Pharma logo

Alembic Pharma Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Alembic Pharma Overview

Alembic occupies an unusual middle position in Indian pharma: too large to be a niche specialist, too small to compete on scale with the top decile. Its distinctiveness lies in vertical integration — captive API supply feeding a formulation base that now spans oral solids, oncology orals and injectables, general injectables, ophthalmics and dermatology — and in an unusually heavy historical R&D commitment that funded a 274-filing ANDA pipeline. The company is the 21st-ranked player in the Indian Pharmaceutical Market with roughly 1.2% share, but derives about two-thirds of revenue from exports, with the US alone at approximately 30%. After a difficult FY2022–FY2024 stretch in which capacity was commissioned faster than it could be filled, FY2026 marked an inflection: revenue grew 10% to INR 7,345 crore, margins recovered to 15.9%, and the company entered US branded specialty pharmaceuticals with Pivya. The open questions are domestic execution, US price erosion and working-capital discipline.

Alembic Pharmaceuticals Limited is the listed pharmaceutical flagship of the Vadodara-based Alembic Group, a vertically integrated developer, manufacturer and marketer of branded formulations for India, generic formulations for regulated and semi-regulated export markets, and active pharmaceutical ingredients (APIs) for captive and third-party use. The company traces its operating heritage to 1907, when Alembic Chemical Works Co. Ltd was founded in Vadodara; the modern listed entity was created by the demerger of Alembic Ltd's pharmaceutical business effective 1 April 2010 and listed in September 2011.


What the company does

Alembic Pharmaceuticals develops, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients. The business is conventionally described by management across four commercial engines:

  1. India Branded Formulations — prescription-driven branded generics sold to Indian physicians through a field force of over 5,500 medical representatives across 21 marketing divisions, plus an Animal Health division.

  2. US Formulations — generic products commercialised in the United States through a wholly owned front-end (Alembic Pharmaceuticals, Inc.), plus, from Q4 FY2026, a branded specialty platform operated through Alembic Therapeutics LLC.

  3. Ex-US International Formulations — generic and branded-generic formulations sold in Europe, Canada, Australia, Brazil, Chile, South Africa, the Middle East and other markets, historically largely through partners, increasingly through owned subsidiaries.

  4. API — active pharmaceutical ingredients supplied captively for Alembic's own formulations and sold to more than 60 countries; 152 cumulative US Drug Master Files filed as at 30 June 2026.

The company describes itself in filings as a vertically integrated, research-and-development-driven pharmaceutical company engaged in the manufacture and marketing of generic pharmaceutical products globally, with research and manufacturing facilities approved by regulators in developed markets including the USFDA. Its stated mission, reproduced in the Q4 FY26 investor presentation, is to improve healthcare with innovation, commitment and trust.

Independent characterisation

Three structural observations bear on how the business should be read.

First, this is not a "domestic branded generics" company despite its Indian heritage. In FY2026, domestic branded formulations were roughly 33% of consolidated revenue, international generic formulations roughly 50%, and API roughly 16% (CARE Ratings, 11 June 2026). The economics of the enterprise are therefore driven far more by US and rest-of-world generic pricing than by the Indian prescription market. That is a materially different risk profile from peers such as Mankind or Alkem, and closer to Ajanta or Ipca, though with a larger US weighting than either.

Second, the revenue model is almost entirely product sales. There is no subscription element, negligible disclosed licensing income, and only modest out-licensing and contract-manufacturing activity, which management referenced in the June 2026 CRISIL rationale as an emerging lever for filling under-utilised capacity at F2 and F3. The nearest thing to a services line is the CMO/out-licensing opportunity set, which is not separately disclosed. Alembic Therapeutics' Pivya is licensed-in/acquired rather than internally discovered, and the two complementary women's-health products added in FY2027 were in-licensed — so the "branded specialty" business is a commercialisation model, not a discovery model.

Third, the value-chain position is unusually deep for a company of this size. Alembic makes its own API for key molecules, formulates across five dosage-form platforms, holds its own US front-end and distribution relationships, and now has its own US branded field force. Vertical integration is a genuine differentiator on supply security and cost, but it also means fixed-cost absorption is the single most important swing factor in margins — which is precisely what has constrained profitability since the FY2019–FY2022 capex cycle.

Customer types and end-markets

BusinessCustomer typeEnd-marketRoute to market
India BrandedPhysicians (prescribers), stockists, retail pharmacyIndian retail prescription marketOwn field force (5,500+ MRs), 21 divisions, ~208 brands
India Animal HealthVeterinarians, poultry and livestock integrators, companion-animal clinicsIndian animal health marketOwn field force within India Branded
US GenericsThree large wholesalers/distributors that control the majority of US drug distribution; retail chains; GPOsUS generic prescription marketAlembic Pharmaceuticals, Inc. (own front-end)
US Branded SpecialtyPrescribing physicians (uUTI/women's health); pharmacy benefit channelUS branded prescription marketAlembic Therapeutics LLC field force; product supplied by CMO
Ex-US GenericsPartner marketing companies (B2B); increasingly direct customers in new markets (B2C)EU, Canada, Australia, Brazil, Chile, South Africa, MEA, LATAMPartners plus new owned subsidiaries (Thailand, Philippines, Germany, Chile, Mexico, UAE)
APIGeneric formulators worldwide; captive internal consumption60+ countriesDirect sales, DMF-supported

Strategy

Stated strategic themes

Management's own framing, drawn from the Q1 FY2027 call and Q4 FY26 presentation, rests on five pillars:

  1. Complex generics and specialty pipeline. Managing Director Pranav Amin framed the operating environment as one in which "execution quality, portfolio choices, manufacturing capabilities, and launch discipline are increasingly becoming the key differentiators." The company describes itself as "strategically evolving the portfolio and pipeline across complex platforms and specialty segments."

  2. US branded platform. Building a scalable US specialty franchise anchored on women's health, with Pivya as the beachhead and additional in-licensed products complementing it.

  3. India chronic and prescription quality. Stated priorities are a robust chronic portfolio, high-quality prescriptions, deeper specialty-physician engagement and sharper commercial execution.

  4. International market expansion via owned front-ends. Converting the ex-US business from pure partner-led B2B to a mixed model with direct presence.

  5. Operating leverage and capital discipline. Debottlenecking, capacity enhancement and better utilisation of newer facilities, with capex held to approximately INR 400 crore annually and funded from internal accruals.

The Q4 FY26 "Value Proposition" slide lists: developing a specialty drug pipeline for India; exploring opportunities in injectables; supplying APIs to 60+ countries; consistent dividend payout; ranking 21st in the Indian formulations market; established presence in Chile and UAE; expanding the product portfolio in the USA; and strengthening presence in Canada, South Africa, LATAM and the Middle East.

Announced strategic initiatives, last 24 months

DateInitiativeDetail
Apr 2025Pithampur (Indore) formulation facility commissionedINR 205 crore; in-housing of third-party India production
May 2025International launch programmeTarget of 40+ new products across EU, Canada, Australia, South Africa in FY2026
Jul 2025Utility Therapeutics acquisitionUSD 12 million, milestone-linked instalments; entry into US branded specialty
Nov 2025UAE branch converted to wholly owned subsidiaryMiddle East formalisation
Nov 2025Margin and R&D guidance resetR&D to be reduced toward 8% of revenue (INR 600–650 crore for FY2026) from a 12–14% historical level; EBITDA margin target of 18–20% over two years
Feb–Mar 2026Pivya US launchFirst branded product; first prescription sale 6 March 2026
Mar–Apr 2026Subsidiaries incorporated in Thailand, Philippines, GermanyDirect market access in new territories
Apr 2026Indore facility WHO certificationOpens semi-regulated export markets from the MP plant
Jun 2026Canada joint venture45% of 17989377 Canada Inc., alongside Difgen Holdings LLC (45%)
2,026Peptide development programmeCited as a primary driver of elevated R&D in Q4 FY2026 and Q1 FY2027
Jul 2026NATCO distribution partnershipAlembic to distribute NATCO-manufactured Olaparib in the US
2,026Saudi Arabia joint ventureReferenced by the Managing Director on the Q1 FY2027 call ("we're doing a JV in Saudi Arabia"); formal terms not publicly disclosed

ESG commitments with targets

CommitmentTargetProgress disclosed
Net Zero emissions2,050SBTi-validated; Alembic is one of only ten Indian pharmaceutical companies with SBTi-approved targets
GHG emission reduction63% by 2034; 90% by 2050Direct emissions reduced approximately 10% in FY2025 against an FY2021 baseline (CRISIL)
Water neutrality2,02785% water neutrality achieved in FY2025; 20% reduction in specific water consumption (KL/MT); 81% of treated water recycled; 112 recharge wells developed (102 as at FY2025 per CRISIL)
Tree planting50,000 trees by 202725,000+ planted
Renewable energyNot separately quantified24 MW solar park commissioned at Bhatpur, Vadodara (built as two 12 MW phases); renewables at approximately 20% of energy mix in FY2025, up from approximately 5% in FY2023
Landfill wasteNot separately quantified16% reduction achieved
Zero fatalityMaintain at all plants and locationsZero workforce fatalities in FY2025 and FY2026; LTIFR 0.03 (employees) and 0.07 (workers) per million person-hours
Supplier ESG assessmentNot separately quantifiedSupplier Code of Conduct and sustainable procurement policy implemented; 27% of critical vendors assessed against ESG criteria
CSR reachNot separately quantified244,460 beneficiaries impacted
Employer certificationMaintain"Great Place to Work" certified for a third consecutive year

Management's medium-term financial targets

MetricGuidanceSource
FY2027 consolidated revenue growthRaised to "closer to the mid-teen range" from low double digitsQ1 FY27 call, 4 Aug 2026
FY2027 US formulation growthMid-to-high teens (INR terms), raised from low-to-mid teensQ1 FY27 call
FY2027 ex-US formulation growth15% (INR terms)Q1 FY27 call
FY2027 API growthAbove 10%Q1 FY27 call
FY2027 India branded growthClose to market growth; "high single-digit" for the year, bridging the gap to IPM growthQ1 FY27 call
FY2027 EBITDA marginBroadly around the Q1 level of 16%; core business improving to high teens, offset by approximately 150 bps dilution from US brandedQ1 FY27 call
FY2027 gross margin70–75% rangeQ1 FY27 call
FY2027 US product launchesApproximately 15 over the remaining nine months; similar volume in FY2028Q1 FY27 call
FY2027 R&D spendINR 750–800 croreQ4 FY26 disclosure, May 2026
Annual capex, medium termApproximately INR 400 crore, internally fundedCRISIL, 30 Jun 2026
US branded breakevenApproaching breakeven end-FY2027; positive contribution FY2028Q1 FY27 call
DebtReduce at least to March 2026 levels during FY2027; target approximately 1xQ1 FY27 call

An earlier and more ambitious framing — EBITDA margins of 18–20% "over the next couple of years," articulated in November 2025 — has effectively been superseded by the more conservative FY2027 guidance of approximately 16%. Investors should treat the 18–20% aspiration as an FY2028-plus scenario contingent on the branded platform turning profitable.

Products & Services

India Branded Formulations — commercial architecture

As at 31 March 2026 the India branded business comprised approximately 208 brands, over 1,000 SKUs (CARE Ratings), a field force of 5,500+ medical representatives organised into 21 marketing divisions, reaching approximately 246,000 prescribers and generating 136.5 million prescriptions on a MAT March 2026 basis. By MAT June 2026 the prescription base had risen to 137.6 million. Alembic ranks 21st in the Indian Pharmaceutical Market with approximately 1.2% value share (IQVIA MAT March 2026) and 17th by prescription volume. Approximately 13% of the product portfolio is listed under the NLEM and therefore subject to DPCO price control.

Four flagship brands exceeded INR 100 crore (INR 1 billion) in annual sales in FY2026; by Q1 FY2027 the company reported five such brands. The top ten domestic brands constituted approximately 37% of branded formulation sales in FY2026 (38% in FY2025), and the top five therapies contributed approximately 75% of domestic revenue.

India Branded — therapy mix

Therapy areaShare of Q4 FY2026 India sales (%)
Animal Health23
Anti-infective16
Gynaecology13
Cardiology13
Cough & Cold9
Gastrology10
Anti-diabetic10
Others6

Source: Q4 FY26 Investor Presentation. The Q1 FY2027 deck reports a slightly different mix — anti-infectives 15%, gynaecology 15%, cardiology 14%, gastrology 11%, animal health 22% — reflecting quarterly seasonality.

The specialty/acute/animal-health split moved from 52% / 30% / 18% in Q4 FY2025 to 52% / 26% / 22% in Q4 FY2026 — evidence of the acute portfolio's structural decline and animal health's rise. On the Q1 FY2027 call the CFO stated that specialty is roughly 60% of India revenue and acute roughly 37%.

India Branded — named brands, rank and market share (MAT March 2026)

BrandMolecule class / indication (where identifiable)Rank in molecule groupMarket share (%)
ROXIDRoxithromycin, macrolide antibiotic194.0
ALTHROCINErythromycin, macrolide antibiotic184.2
DELTONE—151.6
ELATA—154.1
AZITHRALAzithromycin, macrolide antibiotic130.1
GERIJOINTOrthopaedic / joint health130.4
CRINA-NCRGynaecology129.4
ESTROPLUSGynaecology / hormone234.8
LACTONICProbiotic / gastro222.1
TRAVISIGHTOphthalmology (travoprost)219.9
GESTOFIT SRProgesterone, gynaecology218.1
ISOFIT SR—214.5
UNIGOLIXGynaecology213.7
CETANIL—26.7
CLOFFClarithromycin, macrolide antibiotic411.3
OVIGYN DHGynaecology411.0
WIKORYLCough & cold310.1
BLADMIRUro/nephrology38.8
ULGELAntacid / gastro37.6
BROZEET-LSCough & cold36.3
SHARKOFERROLHaematinic (animal health)56.0
ISOFIT—35.7
BILAMBIC-MAnti-allergic45.7
ETRIK—45.0
HARMONI—54.5
VELDROP—44.3
TELLZYTelmisartan, cardiology53.5
FREEGO—28.5

Source: Q4 FY26 Investor Presentation, IQVIA MAT March 2026. Ranks are within the respective molecule group, not the total market.

Other significant brands identified in company and third-party product listings, though without disclosed current rank: REKOOL and REKOOL-D (rabeprazole, gastro), RICHAR CR, GLISEN-MF and GLISEN PM (anti-diabetic), ZEET (cough & cold), MAGADOL (pain), LAVETA and LAVETA-M (levocetirizine, anti-allergic), ROSAVE and ROSAVE-F (rosuvastatin, cardiology), PROTINULES and PROTINULES-PL (nutritional), ULGE-RAFT, ULGEL-A, ETERNEX-M and ETERNEX-T, GERIPOD-D, GERIFLO-D, VITARESP FX, CYCLOSET, ENZICTRA, NEW LIVFIT, OVIGYN D3, WIKORYL-AF, HERMIN, VEHYCAL, VOGO, GLZ PLUS, AL5ZYME, TETAN (telmisartan), D-KOOL (rabeprazole) and STROX.

Named marketing divisions include Megacare (established 1987; infection, allergy and pain management; brands Azithral, Laveta, Magadol), Maxis (cough & cold plus antibiotics, GI, anti-diarrhoeal and pain; brands Althrocin, Wikoryl, Brozeet, Zeet) and the legacy Alembic Pharma division (macrolides: Althrocin, Roxid, Cloff). Pricing is standard Indian branded-generic MRP-based pricing, constrained by DPCO ceilings for NLEM-listed molecules; no per-brand pricing is disclosed.

Animal Health division

MetricFY2022FY2023FY2024FY2025FY2026
Animal Health revenue (INR crore)232281355431519

Source: Q4 FY26 Investor Presentation (reported in INR million). CAGR FY2022–FY2026: 22%.

The division operates across livestock, poultry and companion animal segments and holds market leadership in haematinics and antibiotics. Flagship brands are Sharkoferrol (haematinic), Moxel, Xceft and Mceft. Brand-tier structure as at Q4 FY2026: six brands above INR 30 crore annual sales, one in the INR 20–30 crore band, six in INR 10–20 crore, and 19 in INR 2–10 crore. Q4 FY2026 product mix: antibiotics 38%, feed supplement 27%, tonics 18%, supportive therapy 10%, antiparasitic 7%. Q1 FY2027 mix as reported: tonics 37%, feed supplements 34%.

US Generic Formulations

MetricFY2022FY2023FY2024FY2025FY2026Q1 FY2027
US formulation revenue (INR crore)1,6661,5721,7301,9572,206778
Products commercialised in the US (cumulative)————178185
Cumulative ANDA filings————274279
Cumulative ANDA approvals (incl. tentative)————235244
Dosage formAs at 31 Mar 2026As at 30 Jun 2026
Oral solids158164
Dermatology3133
Ophthalmics2323
Injectables2122
Inhalation22
Total235244
ProductReference brand / innovatorDisclosed US market sizeDate announced
Pantoprazole Sodium for Injection 40 mg/vialProtonix I.V. (Wyeth)USD 48 million1 Apr 2025
Carbamazepine Tablets USP 200 mg—USD 32 million17 Apr 2025
Ticagrelor Tablets 90 mg (final) / 60 mg (tentative)Brilinta (AstraZeneca)USD 1,062 million (90 mg); USD 242 million (60 mg)2 May 2025
Rivaroxaban TabletsXareltoUSD 445 million15 May 2025
Bosutinib Tablets 100 mg and 500 mg (final)Bosulif (PF Prism C.V.)USD 291 million30 May 2025
Doxorubicin Hydrochloride Liposome Injection—USD 29 million30 Jun 2025
Carbamazepine Extended-Release Tablets USP 100/200/400 mgTegretol-XR (Novartis)USD 71 million26 Jul 2025
Tretinoin Cream USP 0.025%Retin-A Cream (Bausch Health)USD 94 million15 Aug 2025
Phytonadione Injectable Emulsion USP 1 mg/0.5 mL PFS—USD 44 million9 Sep 2025
Paroxetine Extended-Release Tablets 25 mg / 37.5 mgPaxil CR (Apotex)—25 Sep 2025
Triamcinolone Acetonide Injectable Suspension USP 40 mg/mLKenalog-40 (Bristol-Myers Squibb)USD 96 million18 Oct 2025
Ticagrelor Tablets 60 mg (final)Brilinta (AstraZeneca)USD 236 million29 Oct 2025
Dasatinib Tablets (six strengths)SprycelUSD 1,017 million7 Nov 2025
Sumatriptan Injection USP autoinjector—USD 73 million7 Nov 2025
Dexlansoprazole Delayed-Release Capsules 30/60 mgDexilant (Takeda)USD 285 million13 Nov 2025
Bosutinib Tablets 400 mg (tentative, sANDA)Bosulif (PF Prism C.V.)USD 251 million12 Jan 2026
Efinaconazole Topical Solution 10%Jublia (Bausch Health)USD 500 million24 Feb 2026
Lamotrigine Orally Disintegrating Tablets 25/50/100/200 mgLamictal ODT (GSK)USD 27 million26 Feb 2026
Paroxetine Extended-Release Tablets USP 12.5 mg (sANDA)Paxil CR—27 Mar 2026
Dapagliflozin Tablets 5 mg / 10 mg (shared 180-day exclusivity)Farxiga (AstraZeneca)USD 10,487 million7 Apr 2026
Methotrexate Injection USP——16 Apr 2026
Macitentan Tablets 10 mgOpsumit (Actelion)—~Apr 2026
Fingolimod Capsules 0.5 mgGilenya (Novartis)USD 145 million25 Apr 2026
Levothyroxine Sodium Tablets USP 25–300 mcgSynthroid (AbbVie)USD 1,869 million22 May 2026
Darolutamide Tablets 300 mg (tentative)NubeqaUSD 3,155 million14 May 2026
Haloperidol Tablets (multiple strengths)—USD 27 million5 Jun 2026
Larotrectinib Capsules 25 mg / 100 mg (tentative; sole first applicant)Vitrakvi (Bayer)USD 91 million12 Jun 2026
Tretinoin Cream USP 0.05%Retin-A Cream 0.05% (Bausch Health)USD 76 million12 Jun 2026
Binimetinib Tablets 45 mg (tentative; sole first applicant, 180-day exclusivity eligible)MektoviUSD 259 million20 Jun 2026
Oseltamivir Phosphate Oral SuspensionTamifluUSD 27 million27 Jun 2026
Dapsone Gel 5%Aczone Gel (Almirall)—29 Jun 2026
Prucalopride Tablets—USD 100 million28 Jul 2026
Olaparib Tablets 100/150 mg (tentative; NATCO-manufactured, Alembic-distributed)Lynparza (AstraZeneca)USD 1,400 million18 Jul 2026

Sources: Q4 FY26 and Q1 FY27 Investor Presentations. As at 30 June 2026 the 244 approvals comprised 224 final and 20 tentative.

Named US products approved or launched in the eighteen months to August 2026, with reference-listed drug and IQVIA-estimated US market size where disclosed by the company:

Sources: company Regulation 30 disclosures and press releases as reported by exchange-filing aggregators. Market sizes are the company's IQVIA-sourced figures for the twelve-month period stated in each release.

Bosutinib deserves specific note. Alembic holds 180-day marketing exclusivity on the 100 mg and 500 mg strengths, confirmed by the Managing Director on the Q1 FY2027 call, with exclusivity running to November 2026. Management characterised the product as low-volume but well-priced, contributed only one month of sales in Q1 FY2027 (launched June 2026), and cautioned that post-exclusivity economics are difficult to forecast given the small volume base.

US Branded Specialty — Alembic Therapeutics

ProductDescriptionStatus
PIVYA (pivmecillinam 185 mg tablets)Oral penicillin-class antibacterial (prodrug of mecillinam), FDA-approved April 2024 for uncomplicated urinary tract infection in women aged 18+ caused by susceptible isolates of E. coli, Proteus mirabilis and Staphylococcus saprophyticus. Reported as the first antibiotic approved for uUTI in approximately two decades.Soft-launched Q4 FY2026; first prescription sale 6 March 2026
MEC (mecillinam, IV)Intravenous formulation under development, positioned for potential first-line therapy in complicated UTI in the hospital settingIn development (acquired with Utility)
Two additional in-licensed women's health productsDescribed by the Managing Director on the Q1 FY2027 call as smaller, complementary rather than competing with Pivya, addressing the same UTI-treating physician baseRecently licensed; commercialisation beginning

The branded model carries no manufacturing investment — product is supplied by a contract manufacturer, and the entire incremental cost base is field force, marketing and promotion. Management guides to breakeven "towards the end of FY2027" with positive contribution from FY2028.

Ex-US International Formulations

MetricFY2022FY2023FY2024FY2025FY2026Q1 FY2027
Ex-US formulation revenue (INR crore)7758521,0521,2431,494383

Active partnership markets disclosed: Europe, Canada, Australia, Brazil, Chile and South Africa. The company also cites established presence in Chile and the UAE, and expansion focus on Canada, South Africa, Latin America and the Middle East. In May 2025 management set a target of launching more than 40 new products across international markets (EU, Canada, Australia, South Africa) during FY2026. This is predominantly a B2B, partner-supplied business, which management explicitly identifies as the reason for quarter-to-quarter revenue lumpiness.

API portfolio

MetricFY2022FY2023FY2024FY2025FY2026Q1 FY2027
API revenue (INR crore)9391,1661,2461,1331,187346
Cumulative US DMF filings————149152

API is supplied to more than 60 countries. Six US DMFs were filed in Q4 FY2026 alone and three in Q1 FY2027. The API-III facility at Karakhadi cleared an ANVISA (Brazil) GMP inspection covering 56 APIs in June 2025 and again in May 2026 without observations. Individual API molecules are not disclosed product-by-product in investor materials; the portfolio is described as covering the anti-infective, gynaecology, cardiology, diabetes, dermatology and oncology therapeutic areas that mirror the formulation business.

Financial Narrative

Basis of presentation and a necessary caveat

Two EBITDA conventions circulate for this company and they do not agree. Screener/C-MOTS presents "operating profit" as revenue less operating expenses, excluding other income and exceptional items. The company's own investor deck presents "EBITDA" including other income and, for FY2023, adjusted to exclude the Aleor write-off. CARE Ratings presents "PBILDT" on a third, slightly different basis. All three are shown below with the basis stated, because the differences are material (FY2023 ranges from INR 682 crore to INR 779 crore depending on convention).

Income statement, FY2022–FY2026 (consolidated): notes and sources

Zeros in the table indicate that the figure is not publicly disclosed or not available on a comparable basis for that year, not a value of nil. Sources: Screener/C-MOTS consolidated data for the full series; Q4 FY26 Investor Presentation for company-basis EBITDA, gross margin and attributable profit; CARE Ratings 11 June 2026 for PBILDT.

Revenue CAGR. FY2022–FY2026: 8.5%. FY2021–FY2026 (five-year): 6.4%. FY2016–FY2026 (ten-year): approximately 9%. Trailing twelve months to June 2026: INR 7,784 crore, up approximately 14% year on year.

Net profit CAGR. FY2022–FY2026: 6.5%. The five-year figure is negative (-9% on a FY2021 base) because FY2021 contained an exceptional COVID-era earnings peak of INR 1,146 crore that has not been repeated.

Commentary on income-statement trends, inflections and drivers

The FY2021 peak and the FY2022–FY2023 collapse. Net profit of INR 1,146 crore in FY2021 was a genuine outlier, built on pandemic-era demand and favourable US pricing. Profit fell 55% to INR 521 crore in FY2022 and a further 34% to INR 342 crore in FY2023. Three forces compounded: US price erosion as pandemic pricing normalised; R&D spend running at 15.8% and 12.8% of sales in FY2022 and FY2023 respectively; and — most importantly — the commissioning of new oncology, injectable, ophthalmic and dermatology plants whose fixed costs hit the P&L years before their volumes did. Operating margin compressed from 27% in FY2021 to 12% in FY2023.

The FY2024–FY2026 recovery. Three levers reversed the decline. R&D was cut hard, to 7.6% of sales in FY2024 from 12.8% the prior year — a INR 240 crore swing that flatters the FY2024 recovery and should be understood as such. Utilisation of F2 and F3 began to improve. And the ex-US business, growing at 18–24% annually off a small base, added high-quality incremental volume. Operating margin recovered to 15.0% in FY2024 and 15.3% in FY2026, with CRISIL computing 15.9% on its basis.

The FY2026 tax anomaly. Reported effective tax rate for FY2026 was 3% versus 18% in FY2025, driven by a large tax credit in Q4 FY2026 (the March 2026 quarter showed a negative 70% tax rate). This is why Q4 FY2026 net profit rose 29% year on year to INR 202.70 crore while profit before tax fell 38% to INR 119 crore. Any read of FY2026 earnings quality that ignores this is misleading: pre-tax profit for FY2026 was INR 694 crore, down 2% on FY2025's INR 707 crore. Management confirmed on the Q1 FY2027 call that the company has migrated to the new tax regime, with a normalised effective rate of approximately 22%.

The R&D re-acceleration. FY2026 R&D rose 37% to INR 710 crore (9.6% of sales), driven by peptide development, exhibit batches and higher filing activity. Q4 FY2026 alone saw R&D up 39% year on year. This is a deliberate re-investment after the FY2024–FY2025 austerity, and it is the principal reason FY2026 EBITDA margin did not expand more than it did.

Finance costs. Interest expense has risen five-fold from INR 18 crore in FY2022 to INR 94 crore in FY2026, entirely on working capital.

Balance sheet, FY2022–FY2026 (consolidated): notes and sources

Zeros denote not publicly disclosed in the sources reviewed. Sources: Screener/C-MOTS consolidated balance sheet; CRISIL Ratings 30 June 2026 for short-term borrowings, lease liabilities and liquid surplus; book value per share for FY2026 per Screener, earlier years computed from equity divided by 19.66 crore shares.

Goodwill and intangibles. Not separately disclosed in the consolidated summary available. Management stated on the Q1 FY2027 call that intangible assets acquired in connection with the US branded business were capitalised in Q4 FY2026 and are being amortised over approximately seven to eight years, and that roughly 70–75% of the year-on-year increase in depreciation in Q1 FY2027 was attributable to that amortisation. The quantum of the intangible is not publicly disclosed; the CFO declined to give the figure on the call.

Working capital. Gross current assets stood at 224 days as at 31 March 2026 versus 222 days a year earlier (CRISIL). Net working capital increased by approximately INR 330 crore during FY2026, primarily on elevated inventory — a deliberate build for planned launches and for stocking key APIs and inputs against geopolitical supply risk.

Cash flow, FY2022–FY2026 (consolidated): notes and sources

Sources: Screener/C-MOTS cash flow statement; Q4 FY26 Investor Presentation for capex. Dividend outflow approximated as DPS multiplied by 19.66 crore shares; note that a fiscal year's declared dividend is typically paid in the following fiscal year. Alembic has not undertaken any share buyback in the period reviewed.

The FY2025 cash flow break is the single most important item in this section. Operating cash flow collapsed to INR 88 crore — a CFO/operating-profit conversion of just 16% against a five-year average near 75% — and free cash flow was negative INR 466 crore. This was funded by a INR 745 crore increase in borrowings (financing inflow of INR 444 crore). The cause was a step-change in working capital: inventory days rose from 350 to 466, receivable days from 60 to 77, and the cash conversion cycle from 253 to 363 days. FY2026 saw a partial normalisation of the cash flow statement (CFO INR 783 crore) but not of the underlying working capital, which deteriorated further on a days basis to a 381-day cash conversion cycle. Gross debt rose again to approximately INR 1,600 crore by 30 June 2026 on higher Q1 receivables. The CFO's stated intention is to return at least to March 2026 levels during FY2027 and then reduce further.

Ratios, FY2022–FY2026: notes and sources

Zeros denote not disclosed or not computable from available sources. ROE, ROA and asset turnover are computed on average balances by the analyst from the balance-sheet series above; other figures are as reported by the stated source.

On ROIC. A clean ROIC is not computable from public disclosure because segment capital employed and the split of "assets not deployed" are undisclosed. An analyst-computed approximation for FY2026 — NOPAT of roughly INR 626 crore (operating profit less depreciation, taxed at a normalised 22%) over average capital employed of roughly INR 6,777 crore — yields approximately 9.2%. The company's own "operating ROCE" of 15% excludes assets not deployed and exceptional items and is therefore not comparable. The gap between the two is itself the story: roughly INR 683 crore of CWIP and a portion of the gross block are not yet earning.

On returns generally. The uncomfortable fact is that ROE has averaged approximately 11% over five years against a cost of equity that any reasonable estimate would place higher, and Screener's three-year ROE is 12.7%. Alembic destroyed returns during the capex build and has not yet re-earned them. FY2026's 12.4% is progress, not vindication.

Quarterly trajectory, Q1 FY2025 to Q1 FY2027: notes and sources

Source: Screener/C-MOTS consolidated quarterly data.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

Segment (INR Cr)FY2022FY2023FY2024FY2025FY2026

India Branded Formulations

1,9262,0632,2002,3392,458

US Formulations

1,6661,5721,7301,9572,206

Ex-US International Formulations

7758521,0521,2431,494

API

9391,1661,2461,1331,187

Total revenue from operations

5,3065,6536,2286,6727,345

Animal Health (subset of India Branded)

232281355431519

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment YoY growth (%)

Segment YoY growth (%)FY2023FY2024FY2025FY2026

India Branded Formulations

7.16.66.35.1

US Formulations

-5.610.013.112.7

Ex-US International Formulations

9.923.518.220.2

API

24.26.9-9.14.8

Total

6.510.27.110.1

Animal Health

21.126.321.220.4

Contribution to revenue (%)

Contribution to revenue (%)FY2022FY2023FY2024FY2025FY2026

India Branded Formulations

36.336.535.335.133.5

US Formulations

31.427.827.829.330.0

Ex-US International Formulations

14.615.116.918.620.3

API

17.720.620.017.016.2

Revenue by Segment (Quarterly)

Segment (INR Cr)Q1 FY2026Q1 FY2027YoY growth (%)

India Branded Formulations

5996427

US Formulations

52377849

Ex-US International Formulations

32838317

API

26134633

Total revenue from operations

1,7112,15026

Income Statement and Margin Analysis (%)

Metric (INR Cr unless stated)FY2022FY2023FY2024FY2025FY2026

Revenue from operations

5,3065,6536,2296,6727,345

Operating profit (excl. other income)

8746829321,0081,121

Operating profit margin (%)

16.512.115.015.115.3

EBITDA, company basis (incl. other income; FY23 Aleor-adjusted)

07799611,0531,177

EBITDA margin, company basis (%)

014.015.016.016.0

PBILDT, CARE Ratings basis

0001,0321,171

Other income and exceptional items, net

56-22856-14

Depreciation and amortisation

287275273279319

Finance costs

1850567994

Profit before tax

625355632707694

Effective tax rate (%)

1743183

Net profit (total, incl. non-controlling interests)

521342616582671

Net profit attributable to shareholders

000583675

Net profit margin (%)

9.86.19.98.79.1

EPS, basic and diluted (INR)

26.5017.4031.3329.6834.33

Dividend per share (INR)

108111112

Dividend payout ratio (%)

3846353735

Gross margin (%)

0007373

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet and Per-Share Data

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Total assets

7,1226,1836,4467,7738,763

Net fixed assets

1,7982,3982,5472,5243,081

Capital work in progress

2,304601524837683

Investments

1189693127141

Other assets (incl. inventory, receivables, cash)

2,9023,0873,2814,2854,858

Equity share capital

3939393939

Reserves and surplus

5,1984,3314,7795,1525,636

Total shareholders' equity

5,2374,3704,8185,1915,675

Total borrowings (incl. lease liabilities)

7177225131,2581,430

Short-term borrowings

004301,1961,239

Lease liabilities

000069

Other liabilities

1,1671,0901,1141,3251,658

Cash and liquid surplus

0000203

Net debt

00001,227

Book value per share (INR)

266222245264289

Cash Flow and Margin Analysis (%)

Metric (INR Cr)FY2022FY2023FY2024FY2025FY2026

Cash from operating activities

55272480388783

Cash from investing activities

-372-448-321-568-506

Cash from financing activities

-217-262-438444-164

Net change in cash

-371445-37113

Free cash flow

128282487-466290

Capital expenditure (company basis)

0412345575432

Operating cash flow / operating profit (%)

77115881679

Dividends declared for the year (approx. outflow)

197157216216236

Share buybacks

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

Return on equity, average equity basis (%)

10.17.113.411.612.4

Return on assets, average assets basis (%)

7.55.19.88.28.1

ROCE, Screener basis (%)

117131313

Operating ROCE, company basis (excl. assets not deployed and exceptionals) (%)

014151615

Debt to equity (x)

0.140.170.110.240.25

Adjusted debt / adjusted net worth, CRISIL basis (x)

0000.240.27

Total debt / EBITDA (x)

0.821.060.551.251.22

Net debt / EBITDA (x)

00001.04

Interest coverage, CARE basis (x)

00013.1012.50

Current ratio, CARE basis (x)

00001.75

Asset turnover, average assets (x)

0.770.850.990.940.89

Debtor days

5668607773

Inventory days

406315350466462

Days payable

178145157179154

Cash conversion cycle (days)

283237253363381

Working capital days

7477888787

Gross current assets (days), CRISIL basis

000222224

R&D as % of revenue

15.812.87.67.89.6

Income Statement and Margin Analysis (%) (Quarterly)

Metric (INR Cr)Q1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue from operations

1,5621,6481,6931,7701,7111,9101,8761,8482,150

Operating profit

237239260271281316292228332

Operating profit margin (%)

151515151617161215

Profit before tax

157180178192190224162119222

Net profit

135153138157154184132202172

EPS (INR)

6.857.807.047.987.859.406.7610.318.80

Revenue by Region

Geography proxy (INR Cr)FY2024FY2025FY2026

India — branded formulations

2,2002,3392,458

United States — formulations

1,7301,9572,206

Rest of world — formulations

1,0521,2431,494

API — global (domestic and export, not split)

1,2461,1331,187

Geography proxy — growth (%)

Geography proxy — growth (%)FY2025FY2026

India — branded formulations

6.35.1

United States — formulations

13.112.7

Rest of world — formulations

18.220.2

API — global

-9.14.8

Valuation Snapshot

MetricValueAs at

Closing price (INR)

831

13 August 2026

Market capitalisation (INR Cr)

16,346

13 August 2026

52-week high (INR)

1,005

Trailing twelve months to Aug 2026

52-week low (INR)

635

Trailing twelve months to Aug 2026

1-year total return (%)

-12

To 13 August 2026

3-year price CAGR (%)

2

To 13 August 2026

5-year price CAGR (%)

2

To 13 August 2026

10-year price CAGR (%)

3

To 13 August 2026

5-year cumulative return (%)

10

To 13 August 2026

Index membership

Nifty Total Market, Nifty Microcap 250, Nifty Smallcap 500, BSE Healthcare, BSE 1000

Current

Valuation Multiples

MultipleAlembicBasis

P/E (TTM)

23.7x

Market cap INR 16,346 crore over TTM PAT INR 690 crore

P/E (FY2026 attributable)

24.2x

Over FY2026 PAT of INR 675 crore

P/E per Screener

21.9x

Screener's own computation, 13 August 2026

P/E per Tickertape

23.4x

At INR 797, 31 July 2026

P/B

2.88x

Book value INR 289 per share

EV / EBITDA (FY2026)

~14.9x

EV of INR 17,573 crore (market cap plus net debt of INR 1,227 crore) over EBITDA of INR 1,177 crore

EV / Sales (FY2026)

~2.39x

Same EV over revenue of INR 7,345 crore

Dividend yield

1.44%

INR 12 DPS at INR 831

3-year average P/E

30.1x

Tijori Finance

3-year average EV/EBITDA

18.7x

Tijori Finance

Source Details

SourceCoverageConsensus ratingAverage target (INR)Range (INR)

Investing.com

10 analysts

Buy (6 buy, 3 hold, 1 sell)

907.70

715 – 1,132

Alpha Spread

Sell-side and buy-side pool

—951.29

722.15 – 1,338.75

Trendlyne (research reports)

10 reports, 4 sources

—1,014—

Trendlyne (consensus estimates)

10 analysts

—930

FY2027 revenue growth 13.2%, profit growth 10.3%

MarketScreener

—

Majority recommend sell or reduce; average target revised down significantly over four months

——

Per-Share Data and Dividends & Capital Returns

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

108111112

Dividend as % of face value

500400550550600

Dividend payout ratio (%)

3846353735

Approximate total dividend outflow (INR Cr)

197157216216236

Credit Ratings

AgencyInstrumentRatingOutlookDateRated amount

CRISIL Ratings

Long-term bank facilities (cash credit, WCDL)

Crisil AA+

Stable

30 June 2026

INR 1,100 crore (enhanced from INR 800 crore)

CRISIL Ratings

Commercial paper

Crisil A1+

—

30 June 2026

INR 1,100 crore

CARE Ratings

Commercial paper

CARE A1+

Not applicable

11 June 2026

INR 1,100 crore

Components

ComponentAmount (INR Cr)As atNotes

Short-term borrowings

1,239

31 March 2026

Broadly flat versus INR 1,196 crore at 31 March 2025, but far above INR 430 crore at 31 March 2024

Lease liabilities

69

31 March 2026

—

Total debt

1,430

31 March 2026

Includes lease liabilities

Gross debt

~1600

30 June 2026

Increase attributed entirely to Q1 receivables

Term debt repayment obligation

Less than 75

Next two years

Per CRISIL

Commercial paper outstanding

150

11 June 2026

ISIN INE901L14CI0, issued 15 April 2026, coupon 6.22%, maturity 15 June 2026, of a rated programme of INR 1,100 crore

Liquid surplus

203

31 March 2026

Per CRISIL

Annual cash accrual expectation

700–800

Medium term

Per CRISIL

Analyst Conclusions

Management guidance summary for FY2027

Revenue growth of approximately mid-teens (raised from low double digits on 4 August 2026); US formulations mid-to-high teens; ex-US formulations 15%; API above 10%; India branded approaching market growth in the high single digits; gross margin of 70–75%; EBITDA margin broadly around 16% with core-business margins in the high teens offset by approximately 150 basis points of US branded dilution; approximately 15 further US launches in the remaining nine months and a similar cadence in FY2028; R&D of INR 750–800 crore; capex of approximately INR 400 crore funded internally; and a reduction of gross debt at least back to March 2026 levels.

Consensus expectations

Consensus of approximately ten analysts points to FY2027 revenue growth of approximately 13.2% and profit growth of approximately 10.3%, with an average twelve-month target of INR 907–1,014. Applying the mid-point of management guidance to FY2026 actuals implies FY2027 revenue of approximately INR 8,300–8,450 crore and, at a 16% EBITDA margin, EBITDA of approximately INR 1,330–1,350 crore.

Bull case

  1. Operating leverage is real and only partly harvested. CRISIL sees margins reaching 16–17% over the medium term purely on better facility utilisation, cost control and launch-led revenue. If F2 and F3 fill through out-licensing and CMO work — a lever management has begun to pull — the incremental contribution margin is very high because the fixed cost is already sunk. On FY2028 revenue of roughly INR 9,500 crore at an 18% margin, EBITDA would be approximately INR 1,710 crore against INR 1,177 crore in FY2026, a 45% increase on 29% revenue growth.

  2. The US branded platform flips from a margin drag to a margin source. It currently costs approximately 150 basis points of consolidated EBITDA and carries no manufacturing capital. Management expects breakeven by end-FY2027 and positive contribution from FY2028. A swing from negative to positive on a 150 basis point base is a 300 basis point delta on a business currently earning 16% — arithmetically the single largest identifiable margin lever the company has.

  3. The pipeline is denser than the valuation implies. 244 approvals with 20 tentative, sole first-applicant status on two oncology molecules with 180-day exclusivity, shared exclusivity on a USD 10.5 billion reference molecule, and a NATCO-partnered route into a USD 1.4 billion market. At 23.7x trailing earnings and 2.9x book, the market is capitalising the current margin structure, not the optionality.

Bear case

  1. The domestic business is structurally impaired, not cyclically weak. Losing roughly 19 basis points of IPM share in a year when the market grew 12–16% is not a soft patch. The portfolio is anchored in anti-infectives, which grow below market; the mega-brands are mature; and the fix depends on one recently appointed sales leader turning around a 5,500-person field force with 26% attrition. Management's own guidance is merely to "bridge the gap" to high single digits — that is, to stop losing share, not to gain it.

  2. FY2027 growth is flattered by items that do not repeat. Bosutinib exclusivity ends in November 2026, and management explicitly warned that post-exclusivity competition on a low-volume, high-price molecule "will be quite drastic." Approximately 10 percentage points of Q1 FY2027 US growth came from rupee depreciation. Strip both out and the underlying US business grew 20–25%, largely on launches that themselves erode. The FY2028 comparison is going to be hard.

  3. Cash generation does not support the growth narrative. Over FY2022–FY2026, cumulative free cash flow was approximately INR 721 crore against cumulative net profit of approximately INR 2,732 crore — a 26% conversion. The cash conversion cycle has lengthened from 237 days in FY2023 to 381 days in FY2026. Working capital has consumed the entire benefit of the earnings recovery and been funded with debt. A company that cannot convert profit to cash cannot fund the US manufacturing footprint that the 2028–2029 tariff schedule may eventually require.

Catalysts and monitorables, next twelve months

ItemTimingWhy it matters
Q2 FY2027 results~November 2026First test of whether the India business shows the "positive trend" management promised within one to two quarters
Bosutinib exclusivity expiryNovember 2026Determines the shape of the H2 FY2027 and FY2028 US base
F3 Karkhadi Establishment Inspection ReportPending since February 2026Closure would remove an open regulatory item at the injectables and ophthalmics facility
Response to the July 2026 Warning LetterOngoingEscalation at the bioequivalence facility would affect the ANDA pipeline broadly
Pivya prescription trajectory and breakevenQ3–Q4 FY2027The 150 basis point margin dilution reverses or it does not
Working capital unwind and debt reductionQ2–Q3 FY2027Management committed to returning at least to March 2026 debt levels
Olaparib Para IV resolutionUnscheduledGates access to a USD 1.4 billion reference market
Larotrectinib and binimetinib final approvalsUnscheduledWould trigger 180-day exclusivities
US tariff policy developmentsContinuous to August 2028Whether Alembic announces any US manufacturing or contract-manufacturing response
Company Secretary succession and further senior appointmentsImmediateGovernance continuity after seven senior departures in eighteen months
FY2027 statutory auditor confirmationFY2027 annual reportThe identity of the auditor following expiry of K C Mehta & Co. LLP's first term is not publicly confirmed

Analyst verdict

Alembic Pharmaceuticals in August 2026 is a company halfway through a genuine operational repair, priced by the market as though the repair may not complete. Both positions are defensible.

The repair is real. FY2026 delivered 10% revenue growth, a 16% EBITDA margin, INR 783 crore of operating cash flow after a disastrous FY2025, and 15 US launches. Q1 FY2027 accelerated to 26% growth and prompted a guidance upgrade. The capex cycle that destroyed returns between FY2022 and FY2024 is complete, capex is capped at INR 400 crore, and the assets are gradually filling. Credit metrics are strong — AA+/Stable, gearing of 0.27x, interest coverage of 12.5x — and there is no equity dilution risk. The pipeline, at 244 approvals with two sole-first-applicant exclusivities pending, is disproportionate to the company's size.

The scepticism is equally well-founded. A 16% EBITDA margin against Ajanta at 26% and Glenmark at 27% is not a rounding error, and neither is a 12% ROE. The domestic business — one-third of revenue and the historic franchise — is losing share in a booming market, and the remedy is a single new sales leader whose effect will not be measurable for two or three quarters. Cash conversion has deteriorated for three consecutive years, and the FY2026 profit figure is materially flattered by a 3% effective tax rate that has already normalised to 22%. Pre-tax profit actually declined in FY2026.

Two facts should dominate the twelve-month view. First, the arithmetic of the US branded platform is unusually clean: it costs 150 basis points today and management expects it to contribute from FY2028. Nothing else on the P&L offers that magnitude of swing on a capital base of essentially zero. Second, the tariff schedule announced on 22 July 2026 puts a date certain — August 2028 — on a strategic decision that approximately 30% of revenue depends upon, and Alembic has said nothing publicly about how it will respond.

At 23.7x trailing earnings, 2.9x book and roughly 15x EV/EBITDA, the shares embed the current margin structure and little of the recovery. That is a reasonable price for an execution story that has disappointed for five years. It is not a bargain, and it will not become one until either the India business stops bleeding share or the cash conversion cycle comes back inside 300 days. Watch the working capital first; margins will follow.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NamePositionEffective / tenureBackground

Chirayu R. Amin

Executive Chairman (from 1 April 2026, five-year appointment approved at the 15th AGM); previously Chairman & CEO from April 2016 to 31 March 2026

Board tenure spans decades; CEO tenure approximately 9.1 years to March 2026

Third-generation entrepreneur; B.A., Maharaja Sayajirao University of Baroda; MBA, Seton Hall University, New Jersey, USA. Over three decades of pharmaceutical industry experience. Former Chairman of the Indian Premier League and Vice President of the BCCI. Trustee of Bhailal Amin General Hospital, Uday Education Society and Bal Utkarsh Society.

Pranav C. Amin

Managing Director; re-appointed for five years effective 1 April 2026

Managing Director since 2015; heads International Business

Son of Chirayu Amin. Leads the international generics, US and API franchises.

Shaunak C. Amin

Managing Director

Approximately 10 years in the role

Son of Chirayu Amin. Historically responsible for the India branded business.

Raj Kumar (R. K.) Baheti

Non-Executive Non-Independent Director from 1 April 2026; previously Director (Finance) & Chief Financial Officer

Postal ballot approval 99.74%, results declared 2 April 2026

Over 44 years in finance; commerce graduate; Fellow of both ICAI and ICSI. Previously in a senior finance role at Sun Pharmaceutical Industries Ltd.

Ashok Barat

Independent Director

Joined the Board in 2024–25

Career finance and general management executive

Manish Kejriwal

Independent Director

Serving as at the 16th AGM

Investment and private equity background

Geeta Goradia

Independent Director

Effective 3 February 2025; shareholder approval 94.70%

Managing Director of Jewel Consumer Care Pvt. Ltd. Prior independent directorships at Panasonic Energy India, Transpek Industries, Gujarat State Fertilizers & Chemicals and Sabarmati Gas. Former Chairperson of FICCI Gujarat; first woman President of the Federation of Gujarat Industries.

Jai Diwanji

Independent Director

Serving

Legal background

Sujit Jaysukh Bhayani (DIN 01767427)

Independent Director

Appointed by circular resolution effective 18 June 2026; approved at the 16th AGM on 5 August 2026, with recorded dissent

Background not disclosed in reviewed sources

Executive Leadership Team

NamePositionNotes

G. Krishnan

Chief Financial Officer

Present in all FY2026 and Q1 FY2027 earnings calls and at the 16th AGM

Udit C. Amin

Chief Business Development Officer

Third son of Chirayu Amin; holds 0.51% of equity

Dr. J. Raman

Chief Scientific Officer

—

Ramesh Juneja

Executive Vice President — Human Health (Sales and Marketing), India Business

Designated SMP with effect from 2 June 2026; Atul Suri and Prag Goel now report to him and ceased to be SMPs

Craig Salmon

President, Alembic Pharmaceuticals, Inc. (US operations)

—

Ajay Kumar Desai

Senior Vice President — Finance; investor relations contact

—

Isha Lamba

Head — Investor Relations and Corporate Development

Hosts earnings calls

Tushar Mehta

Head — R&D (API)

Appointed effective 3 June 2026; 24+ years in API R&D, 100+ development programmes, teams of up to 200 scientists

Amit Nayak

Vice President — Commercial Excellence

Designated SMP effective 1 May 2026; 12 years' experience; PGDM (IMT Ghaziabad), B.Tech (Pharmaceutical Sciences); previously JB Chemicals, Cipla, IMS and EY

Sudhakar Pandiyan

Head of Technical Operations

Less than one year tenure as at FY2025 disclosure

Manisha Saraf

Company Secretary and Compliance Officer

Resigned effective 10 August 2026

Executive Leadership Team by Executive

ExecutivePositionTotal compensation (INR Mn)Notes

Chirayu Amin

Executive Chairman (then Chairman & CEO)

193.80

Approximately 48.4% salary, 51.6% variable/bonus

Pranav Amin

Managing Director

190.90—

Shaunak Amin

Managing Director

122.20—

Raj Kumar Baheti

Director (Finance) & CFO

56.90—

Ajay Desai

Senior Vice President — Finance

9.20—

J. Raman

Chief Scientific Officer

8.41—

Udit Amin

Chief Business Development Officer

8.30—

Gautam Chatterjee

Senior Vice President

8.12—

Shareholding Pattern

CategoryMar 2024 (%)Mar 2025 (%)Mar 2026 (%)Jun 2026 (%)

Promoter and promoter group

69.6169.6769.7469.87

Foreign institutional investors / FPIs

4.463.944.264.17

Domestic institutional investors

15.3916.4316.1715.93

— of which mutual funds

7.829.208.180

— of which insurance companies

7.106.887.680

Public and others

10.549.969.8310.00

Number of shareholders

76,56791,33686,43286,796

Major Shareholders

RankHolderSharesStake (%)
1

Nirayu Private Limited (promoter group)

70,070,70035.65
2

Alembic Limited (promoter group)

56,097,54428.54
3

Life Insurance Corporation of India

8,495,1254.32
4

DSP Midcap Fund

8,316,0214.23
5

Chirayu Ramanbhai Amin (promoter)

4,192,5292.13
6

Tata AIA Life Insurance Co. Ltd — Unit Linked Multi Cap Fund

3,558,3281.81
7

Kotak Small Cap Fund

3,427,7661.74
8

Malika Chirayu Amin (promoter)

3,005,7301.53
9

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D.) Fund

2,207,3901.12
10

Pranav Chirayu Amin / Shaunak Chirayu Amin / Udit Chirayu Amin (each)

1,009,800 / 1,006,980 / 1,006,980

0.51 each

Competitive Landscape

Competitors by Segment

SegmentPrincipal named competitors

India branded formulations — anti-infectives and acute

Cipla, Abbott India, Mankind Pharma, Alkem Laboratories, Macleods, Zydus Lifesciences, GSK Pharmaceuticals India

India branded formulations — chronic/specialty

Torrent Pharmaceuticals, Sun Pharmaceutical Industries, Mankind Pharma, USV, Eris Lifesciences, Ipca Laboratories, Ajanta Pharma, Intas

India animal health

Zydus Animal Health, Virbac India, Zoetis India, Elanco India, Ceva

US generics — oral solids and complex generics

Zydus Lifesciences, Lupin, Aurobindo Pharma, Dr. Reddy's Laboratories, Sun Pharma (Taro), Glenmark, Ajanta Pharma, Amneal, Teva, Viatris/Sandoz

US generics — oncology and injectables

Natco Pharma, Zydus, Dr. Reddy's, Gland Pharma, Eugia (Aurobindo), Cipla

US generics — ophthalmics and dermatology

Sun Pharma (Taro), Glenmark, Amneal, Padagis, Perrigo

Ex-US regulated markets (EU, Canada, Australia, LATAM)

Torrent, Zydus, Lupin, Aurobindo, Glenmark, Intas (Accord), Stada, Sandoz

API merchant supply

Divi's Laboratories, Aarti Pharmalabs, Laurus Labs, Neuland Laboratories, Granules India, Chinese API producers

Peer Comparison FY2026

MetricAlembic PharmaceuticalsAjanta PharmaGlenmark PharmaceuticalsCipla

FY2026 revenue (INR Cr)

7,3455,45316,98328,163

FY2026 revenue growth (%)

1017282

FY2026 EBITDA (INR Cr)

1,1771,3954,5725,925

FY2026 EBITDA margin (%)

16262721

FY2026 net profit (INR Cr)

6751,0561,3623,879

FY2026 net margin (%)

919814

FY2026 R&D as % of revenue

10007

FY2026 ROCE (%)

133300

Key Competitors

PeerFY2026 revenue (INR Cr)Notable FY2026 datapoint

Cipla

28,163

One India business above INR 12,680 crore; North America revenue down 13% to USD 780 million

Zydus Lifesciences

27,150

EBITDA margin 31.2%, the highest in company history; 508 cumulative ANDA filings, 435 approvals; R&D INR 2,273.2 crore (8.4%)

Lupin

27,488

US business at USD 1.3 billion, up approximately 40%; 430 cumulative ANDA filings, 344 approvals, 52 FTFs including 22 exclusive; R&D INR 2,063.1 crore (7.5%)

Glenmark

16,983

Revenue +27.5%; AbbVie/IGI deal with USD 700 million upfront and USD 1.925 billion potential value

Alembic Pharmaceuticals

7,345

274 cumulative ANDA filings, 235 approvals; R&D INR 710 crore (9.6%)

Ajanta Pharma

5,453

US generics +49%; India +14%; ROCE 33%

Recent Developments

--

Company Snapshot

$848.2M

Revenue

17,200

Employees

1907

Founded

Gujarat, India

Headquarters

SWOT Analysis

Strengths

  • Near-monopoly domestic macrolide franchise. Roxid holds 94.0% and Althrocin 84.2% of their respective molecule groups (IQVIA MAT March 2026), with Azithral at 30.1% — three positions that are extremely difficult to dislodge.
  • Deep and productive ANDA pipeline. 279 cumulative filings and 244 approvals as at 30 June 2026, including sole first-applicant status on larotrectinib and binimetinib and shared exclusivity on dapagliflozin — a pipeline density unusual for a company with INR 7,345 crore of revenue.
  • Genuine vertical integration. Captive API supply for key molecules across three USFDA-current API blocks (Panelav API-I/II, Karakhadi API-III), which CARE identifies as partial insulation from supply and price volatility.
  • Balance sheet strength and credit standing. CRISIL AA+/Stable and A1+, gearing of 0.27x, interest coverage of 12.5x, and enhanced rated bank facilities of INR 1,100 crore as at June 2026.
  • Animal Health compounding. Revenue grew from INR 232 crore in FY2022 to INR 519 crore in FY2026, a 22% CAGR, with six brands above INR 30 crore and leadership in haematinics and antibiotics.
  • Regulatory track record. All operational manufacturing facilities held Establishment Inspection Reports as at June 2026 (CARE); API-III cleared USFDA with zero observations in March 2025 and ANVISA without observations in both June 2025 and May 2026.
  • ESG credibility. One of only ten Indian pharmaceutical companies with SBTi-validated net-zero targets; 24 MW solar park commissioned; 81% treated-water recycling; zero fatalities.

Weaknesses

  • Persistent margin deficit. FY2026 EBITDA margin of 16% against Ajanta's 26%, Glenmark's 27% and Cipla's 21% — a gap of 500–1,100 basis points against directly comparable peers.
  • Chronic under-utilisation of new capacity. CRISIL states explicitly that profitability "remains constrained by sub-optimal utilisation of new facilities, particularly F2 and F3," five years after the capex cycle began. INR 683 crore of CWIP remained on the balance sheet at 31 March 2026.
  • India market share erosion. IPM share fell from approximately 1.4% (March 2025) to approximately 1.21% (March 2026); excluding animal health, domestic branded formulations grew approximately 2% in FY2026 against an IPM growing in double digits.
  • Working capital deterioration. Cash conversion cycle extended from 253 days (FY2024) to 381 days (FY2026); inventory days at 462; gross current assets at 224 days; FY2025 operating cash flow of just INR 88 crore against operating profit of INR 1,008 crore (16% conversion).
  • Sub-scale US presence. US revenue of approximately INR 2,206 crore in FY2026 against Lupin and Zydus each at roughly USD 1.3 billion — a fifth of peer scale in a market where scale determines pricing power.
  • Weak returns on capital. Five-year average ROE of approximately 11%; three-year ROE of 12.7%; analyst-computed FY2026 ROIC of approximately 9.2% including non-deployed assets.
  • Senior management instability. Seven senior departures or cessations disclosed in eighteen months, including the President of Supply Chain, two Resident Directors, the Head of Formulation Business Development, an SVP of Strategy, an AVP of Sales & Marketing and the Company Secretary; FY2025 attrition of 26%.
  • Promoter compensation concentration. Aggregate FY2025 promoter-executive remuneration of approximately INR 507 million equates to roughly 8.7% of attributable net profit.

Opportunities

  • US branded specialty scale-up. Management guides Pivya and the two complementary in-licensed products to breakeven by end-FY2027 and positive contribution from FY2028, with an asset-light structure requiring no manufacturing capex.
  • Large-market approvals not yet monetised. Dapagliflozin (USD 10,487 million reference market, shared exclusivity), levothyroxine (USD 1,869 million), darolutamide (USD 3,155 million, tentative) and olaparib (USD 1,400 million via NATCO) represent an unusually large aggregate addressable set.
  • Exclusivity monetisation. Sole first-applicant status on larotrectinib (USD 91 million) and binimetinib (USD 259 million) carries 180-day exclusivity on final approval.
  • Capacity absorption as pure operating leverage. With capex held to INR 400 crore and F2/F3 utilisation improving, incremental volume drops through at high contribution margins — CRISIL sees margin reaching 16–17% over the medium term on this basis alone.
  • Ex-US direct-market conversion. New subsidiaries in Thailand, the Philippines, Germany, Chile, Mexico and the UAE, plus the Canadian JV, convert a partner-margin B2B business into a higher-margin direct model.
  • Out-licensing and CMO. CRISIL identifies out-licensing and contract manufacturing as explicit levers for filling F2 and F3 in the current fiscal year.
  • India commercial reset. New sales leadership under Ramesh Juneja, territory-level review, and AI/automation deployment in field-force execution create a credible path back to market-level domestic growth.
  • Peptides. The programme driving the R&D step-up positions Alembic in one of the few generic categories with durable pricing.

Threats

  • US generic tariffs. Zero tariff to August 2028, then 100%, then 200% from August 2029. Approximately 30% of Alembic revenue is in the affected channel, and the company has disclosed no US manufacturing plan.
  • Regulatory escalation. A USFDA Warning Letter dated 10 July 2026 to the clinical investigator at the Vadodara bioequivalence facility, following a Form 483 in March 2025. Bioequivalence data underpins every ANDA; sustained scrutiny of this facility would be materially more damaging than a manufacturing observation. F3 Karkhadi also has an open Form 483 from February 2026 with the EIR awaited.
  • Bosutinib cliff. Exclusivity expires in November 2026, and management stated that because volumes are small, post-exclusivity competition "will be quite drastic." A meaningful part of FY2027 US outperformance is not repeatable in FY2028.
  • The MGVCL litigation. Supplementary invoices of INR 421.68 crore are being contested in the Gujarat High Court; an adverse outcome would represent approximately 63% of FY2026 net profit.
  • DPCO expansion. Approximately 13% of the portfolio is already NLEM-listed; fresh inclusions would compress domestic pricing further.
  • Continued domestic share loss. If the Juneja-led reset does not restore market-level growth within the two-to-three quarters management has indicated, the 1.2% IPM share becomes structurally impaired.
  • Working capital funding. Gross debt reached approximately INR 1,600 crore by June 2026. CARE's stated negative rating trigger is gearing above 0.5x on a sustained basis; the company is at 0.25–0.27x, so headroom exists — but the direction of travel is unfavourable.
  • Solvent and input cost inflation attributed to Middle East disruption, which management cited as a Q1 FY2027 gross-margin headwind.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
3–7 Mar 2025USFDA inspection of the Bioequivalence Facility, Vadodara; Form 483 with one procedural observationPrecursor to the July 2026 warning letter
13 Mar 2025Alembic Lifesciences Inc. incorporated in Delaware, USAUS structural expansion
17–21 Mar 2025USFDA GMP inspection at API-III, Karakhadi; zero Form 483 observationsClean regulatory outcome at a key API site
18 Mar 2025Geeta Goradia's independent directorship approved with 94.70% shareholder supportBoard refresh completed
1 Apr 2025USFDA final approval — Pantoprazole Sodium for Injection 40 mg/vial (USD 48 million market)Injectables portfolio build
17 Apr 2025USFDA final approval — Carbamazepine Tablets USP 200 mg (USD 32 million market)—
26 Apr 2025New formulation facility commissioned at Pithampur, Madhya Pradesh; investment approximately INR 205 croreIn-housing of third-party India production
2 May 2025USFDA final approval — Ticagrelor 90 mg; tentative — 60 mg (USD 1,062 million and USD 242 million markets)Large cardiovascular opportunity
6 May 2025FY2025 results: Q4 revenue INR 1,769.60 crore (+16.7% YoY), net profit INR 157 crore (-11.8%); dividend of INR 11 per share proposedEarnings quality questions emerge
6 May 2025International launch target announced: 40+ new products across EU, Canada, Australia, South Africa in FY2026Ex-US ambition formalised
7 May 2025R&D guidance: INR 500 crore FY2025, INR 600–650 crore FY2026Deliberate re-investment signalled
15 May 2025USFDA final approval — Rivaroxaban Tablets (USD 445 million market)—
26–31 May 2025Unannounced routine cGMP inspection at API-I & II, Panelav; Form 483 with four observations, none data-integrity relatedMid-severity regulatory event
30 May 2025USFDA final approval — Bosutinib Tablets 100 mg and 500 mg (USD 291 million market)The molecule that would drive Q1 FY2027
18 Jun 2025Establishment Inspection Report received for API-III, KarakhadiClosure of the March 2025 inspection
30 Jun 2025USFDA final approval — Doxorubicin Hydrochloride Liposome Injection (USD 29 million market)Complex injectable capability
3 Jul 2025Acquisition of UTILITY therapeutics Ltd for approximately USD 12 millionStrategic entry into US branded specialty
26 Jul 2025CRISIL reaffirms AA+/Stable; rated bank loan amount enhanced from INR 600 crore to INR 800 crore. USFDA approval — Carbamazepine ER Tablets (USD 71 million market)Credit capacity expanded
31 Jul 2025Shreekumar Nair, President — Supply Chain Management and Operations, retires on superannuationSenior operational departure
5 Aug 2025Q1 FY2026 results: revenue INR 1,710.72 crore (+10%), EBITDA INR 288 crore (+20%), net profit INR 154.38 crore (+15%)Recovery under way
15 Aug 2025USFDA final approval — Tretinoin Cream USP 0.025% (USD 94 million market)Derma build-out
9 Sep 2025USFDA final approval — Phytonadione Injectable Emulsion prefilled syringe (USD 44 million market)—
13 Sep 2025Establishment Inspection Report received for API-I & II, PanelavClosure of the May 2025 Form 483
25 Sep 2025USFDA final approval — Paroxetine ER Tablets 25 mg and 37.5 mg—
18 Oct 2025USFDA final approval — Triamcinolone Acetonide Injectable Suspension (USD 96 million market)—
29 Oct 2025USFDA final approval — Ticagrelor 60 mg (USD 236 million market)Completion of the ticagrelor franchise
4 Nov 2025Q2 FY2026 results: revenue INR 1,910 crore (+15.9%), net profit INR 185 crore (+23.3%), EBITDA margin 16.5% (+194 bps)Best margin print in three years
6 Nov 2025Guidance update: US gross margin 70–75%; R&D to be reduced toward 8% of revenue; API growth 10%; EBITDA margin ambition 18–20% over two yearsThe most bullish margin framing of the period; later moderated
7 Nov 2025USFDA final approvals — Dasatinib Tablets six strengths (USD 1,017 million market) and Sumatriptan Injection autoinjector (USD 73 million), the company's first drug-device combinationOncology and device capability
7 Nov 2025UAE branch converted into wholly owned subsidiary for AED 50,000Middle East formalisation
13 Nov 2025USFDA final approval — Dexlansoprazole DR Capsules (USD 285 million market)209th final approval
16 Dec 2025Writ petitions filed in the Gujarat High Court against Madhya Gujarat Vij Company Limited (MGVCL) disputing supplementary invoices totalling INR 421.68 crore relating to a rooftop solar PV installationThe largest single disclosed contingent legal exposure
12 Jan 2026USFDA tentative approval — Bosutinib Tablets 400 mg via sANDA (USD 251 million market)Lifecycle extension
31 Jan 2026Superannuation of Mr. Ashok Pandya, Resident DirectorManagement churn
5 Feb 2026Q3 FY2026 results: revenue INR 1,876.31 crore (+10.8%), net profit INR 132.97 crore (-3.9%) after an exceptional item of INR 42.23 crore for the new Labour CodesFirst Labour Codes charge
Feb 2026USFDA inspection resulting in a Form 483 with two observations (F3 Karkhadi, per the Q4 FY26 facility table)Response submitted; EIR awaited as at May 2026
24 Feb 2026USFDA final approval — Efinaconazole Topical Solution 10% (USD 500 million market)234th ANDA approval; technically complex topical
26 Feb 2026USFDA final approval — Lamotrigine ODT four strengths (USD 27 million market)—
27 Feb 2026Postal ballot notice: appointment of R. K. Baheti as Non-Executive Non-Independent Director; approval of professional fees up to INR 2.5 crore per annumGovernance transition begins
6 Mar 2026First prescription-based sale of Pivya in the United StatesMilestone: first US branded revenue
9 Mar 2026Alembic Pharmaceuticals (Thailand) Co., Ltd incorporated (99.99%, THB 3,000,000)ASEAN entry
27 Mar 2026USFDA final approval — Paroxetine ER Tablets 12.5 mg via sANDA—
1 Apr 2026Chirayu Amin appointed Executive Chairman; Pranav Amin re-appointed MD for five years; R. K. Baheti appointed Non-Executive Non-Independent Director with 99.74% approvalLeadership transition executed
1 Apr 2026Resignation of Nilesh Wadhwa, Head — Formulation Business Development, effective 31 March 2026Management churn
7 Apr 2026USFDA final approval — Dapagliflozin Tablets 5 mg and 10 mg with shared 180-day exclusivity (USD 10,487 million reference market)Largest reference market in the portfolio
16 Apr 2026USFDA final approval — Methotrexate Injection USP236th approval
~Apr 2026USFDA final approval — Macitentan Tablets 10 mg (Opsumit equivalent); USFDA approval — Lamotrigine TabletsPulmonary arterial hypertension entry
22 Apr 2026Alembic Lifesciences Philippines Inc. incorporated (99.99%, PHP 12,000,000)ASEAN expansion
24 Apr 2026Alembic Pharmaceuticals GmbH incorporated in Germany (EUR 25,000)EU direct presence
25 Apr 2026USFDA final approval — Fingolimod Capsules 0.5 mg (USD 145 million market)237th approval
26–27 Apr 2026Demise of Mr. Saibal Mukherjee, Resident Director (Delhi office), with the company since 2014—
1–2 May 2026Amit Nayak designated Senior Management Personnel; Goldee Pardesi (AVP Sales & Marketing) resignsCommercial team reshuffle
14 May 2026USFDA tentative approval — Darolutamide Tablets 300 mg (USD 3,155 million reference market)Large oncology optionality
15 May 2026Q4 and FY2026 results: Q4 revenue INR 1,847.72 crore (+4.4%), PAT INR 202.70 crore (+29.2%); FY2026 revenue INR 7,344.90 crore (+10%), PAT INR 674.77 crore (+16%); dividend of INR 12 per share (600%) recommended; FY2027 guidance of low double-digit revenue growth and R&D of INR 750–800 croreFull-year inflection confirmed; tax-driven Q4 profit
15 May 2026Resignation of Rohit Garg, Senior Vice President — Strategy & Business Excellence, effective 14 May 2026Management churn
16 May 2026ANVISA GMP inspection cleared at Karakhadi API-III without observationsBrazil market continuity
19 May 2026Promoters declare no share encumbrance during FY2025-26 (34 promoter and promoter-group entities)Governance positive
22 May 2026USFDA final approval — Levothyroxine Sodium Tablets USP, 25–300 mcg (USD 1,869 million reference market)239th approval; very large but highly competitive market
29 May 2026Participation in the Trinity India 2026 institutional investor conference, Mumbai—
2–3 Jun 2026Ramesh Juneja designated SMP as EVP — Human Health (Sales and Marketing), India; Tushar Mehta appointed Head — R&D (API)The India commercial fix begins
5 Jun 2026USFDA final approval — Haloperidol Tablets, multiple strengths (USD 27 million market)—
6–8 Jun 2026Shareholders' Agreement for 45% of 17989377 Canada Inc.Canada front-end
10 Jun 2026Record date of 29 July 2026 fixed for the FY2026 dividend—
11 Jun 2026CARE Ratings reaffirms CARE A1+ on an enhanced INR 1,100 crore commercial paper programmeCredit stability
12 Jun 2026USFDA tentative approval — Larotrectinib Capsules (USD 91 million market), sole first applicant, 180-day exclusivity eligible; final approval — Tretinoin Cream 0.05% (USD 76 million)Exclusivity optionality
18–19 Jun 2026Sujit Jaysukh Bhayani appointed Independent Director for five yearsBoard addition
20 Jun 2026USFDA tentative approval — Binimetinib Tablets 45 mg, sole first applicant with 180-day exclusivity (USD 259 million market)Second exclusivity in a month
22–25 Jun 2026One-on-one investor meetings with HDFC MF, Tata MF, DSP MF and HDFC Life—
27 Jun 2026USFDA final approval — Oseltamivir Phosphate Oral Suspension (USD 27 million market)243rd approval
29 Jun 2026USFDA final approval — Dapsone Gel 5% (Aczone equivalent)244th approval
30 Jun 2026CRISIL reaffirms Crisil AA+/Stable and Crisil A1+; rated bank debt enhanced from INR 800 crore to INR 1,100 crore. Block trade of 432,102 shares at INR 788.65 (INR 34.08 crore) on the NSECredit capacity and institutional churn
10–14 Jul 2026USFDA Warning Letter dated 10 July 2026 issued to the Clinical Investigator associated with a bioequivalence study at the Vadodara Bioequivalence Facility, following the March 2025 inspection; observations relate solely to the Informed Consent Form. Company states no data-integrity concern, no operational restriction and no material financial impactThe most significant regulatory event of the period
18 Jul 2026Partner NATCO Pharma receives USFDA tentative approval for Olaparib Tablets; Alembic to distribute in the US (USD 1.4 billion reference market); Para IV litigation ongoingLarge optionality, gated by litigation
22 Jul 2026US President announces a phased generic drug tariff plan: zero tariff from 1 August 2026 for two years, 100% from August 2028 for one year, 200% from August 2029The dominant medium-term industry risk
28 Jul 2026USFDA final approval — Prucalopride Tablets (USD 100 million market)—
4 Aug 2026Q1 FY2027 results: revenue INR 2,149.77 crore (+26%), EBITDA INR 348 crore (+21%), PBT INR 223 crore (+17%), PAT INR 173.07 crore (+12%); FY2027 revenue growth guidance raised to mid-teensGuidance upgrade
5 Aug 202616th AGM: FY2026 accounts adopted, INR 12 dividend approved, Pranav Amin re-appointed, Sujit Bhayani's independent directorship approved with recorded dissent—
6 Aug 2026Dividend payment commences—
10 Aug 2026Resignation of Ms. Manisha Saraf as Company Secretary, Compliance Officer and Nodal OfficerLatest senior departure

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue from operations rose from INR 53,060 Mn in FY2022 to INR 73,450 Mn in FY2026.
Alembic Pharma — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations53,06056,53062,29066,72073,450

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.